Bevacizumab news

All news on Bevacizumab (also known as Avastin): plants, production capacities, investments and involved companies.

19 October 2025
Raludotatug Deruxtecan Shows 50.5% Response in Platinum-Resistant Ovarian Cancer, Reports Daiichi Sankyo and Merck
Raludotatug deruxtecan achieved a 50.5% response rate in phase 2 for platinum-resistant ovarian cancer, with a 5.6 mg/kg dose selected for phase 3.

Who will be producing Bevacizumab in the future?

Find out with chemXplore Analytics